Fixed-tumor vaccine: A practical formulation with cytokine-microspheres for protective and therapeutic antitumor immunity
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Objective: To study the protective and therapeutic antitumor immunity against hepatocellular carcinoma (HCC) with the fixed-tumor vaccine.Methods: A tumor vaccine consisting of fixed tumor cells or fixed tumor fragments combined with sustained-releasers of cytokines and a non-toxic adjuvant was developed. C57BL/6J mice were immunized intra-dermally with the vaccine on day 0 and 7, followed by intrahepatic challenge with live Hepa 1–6 cells.Results: All of 15 nonimmunized control mice developed the hepatoma. Protection of mice immunized with fixed Hepa 1–6 cells and both of IL-2/GM-CSF microspheres or further mixed with TiterMax Gold reached 80% and 87%, respectively. Mass growth of the established tumors, vaccinated twice at 5 mm in diameter, the tumor of control animals continued to grow. However, 7–10 days after the second injection of the tumor vaccine, the tumor growth was suppressed in 9 of 10 mice and then markedly reduced. Complete tumor regression was observed in 60% (6/10) of mice. Splenocytes from the control mice were not able to lyse target Hepa 1–6 cells and other tumor cells. In contrast splenocytes from the vaccinated mice exhibited a 41% lytic activity against the Hepa 1–6 cells tested at an effector/target (E/T) ratio of 5, whereas they did not exhibited such activity against the melanoma cells (B16-F1), Lewis lung carcinoma cells (LLC), renal carcinoma cells (Renca), and bladder carcinoma cells (MBT-2). The cytotoxic activity was inhibited by the treatment with anti-CD3, anti-CD8, and anti-MHC-class I monoclonal antibodies but not with anti-CD4 and anti-MHC-class II antibodies. In the Phase-I clinical trial, vaccination of HCC patients with the autologous vaccine is a well-tolerated treatment and induces fixed tumor fragment-specific immunity.Conclusion: Fixed HCC vaccination elicited protective and therapeutic antitumor immunity against HCC. The tumor vaccine elicited antigen specific CTL response lysis of the target HCC was mediated by the typical MHC-class I restricted CD8+ T cells.
- Berd D, Maguire HC Jr, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res, 1986, 46: 2572–2577.
- Livingston PO, Albino AP, Chung TJ,et al. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer, 1985, 55: 713–720. CrossRef
- Berd D, Maquire HC Jr, McCue P,et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol, 1990, 8: 1858–1867.
- McCune CS, O’Donnell RW, Marquis DM,et al. Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother, 1990, 32: 62–66. CrossRef
- Soiffer R, Lynch T, Mihin M,et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA, 1998, 95: 13141–13146. CrossRef
- Johbston D, Bystryn JC. Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine. J Natl Cancer, 1991, 83: 1240–1245. CrossRef
- Powles RL, Russell JA, Selby PJ,et al. Maintenance of remission in acute myelogenous leukemia by a mixture of B.C.G. and irradiated leukemia cells. Lancet, 1977, 26: 1107–1110. CrossRef
- Coutelle C, Douar AM, Colledge WH,et al. The challenge of fetal gene therapy. Nature Med, 1995, 1: 864–866. CrossRef
- Huang L, Li S. Liposomal gene delivery: A complex package. Nature Biotechnology, 1997, 15: 620–621. CrossRef
- Protti MP, Bellone M. Immunotherapy: natural versus synthetic peptides. Immunology Today, 1998 19: 98.
- Mayordomo JL, Zorina T, Storkus WJ,et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med, 1995, 1: 1297–1302. CrossRef
- Gong J, Chen D, Kashiwaba M,et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med, 1997, 3: 558–561. CrossRef
- Guo Y, Wu M, Chen H,et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science, 1994, 263: 518–520. CrossRef
- Pardoll DM. Cancer vaccines. Nature Medicine Vaccine Supplement, 1998, 4: 525–531. CrossRef
- Lin SQ, Saijo K, Todoroki T,et al. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nature Med, 1995, 1: 267–271. CrossRef
- Liu SQ, Shiraiwa H, Kawai K,et al. Tumor-specific autologous cytotoxic T lymphocytes from tissue section. Nat Med, 1996, 2: 1283. CrossRef
- Kim C, Matsumura M, Saijo K,et al. In vitro induction of HLA-A2404-restricted and- carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother, 1998, 47: 90–96. CrossRef
- Albert ML, Pearce SF, Francisco LM,et al. Immature dendritic cells phagocytose apoptotic cells via alphav-beta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med, 1998, 188: 1359–1368. CrossRef
- Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nature Med, 1999, 5: 1249–1255. CrossRef
- Volgmann T, Klein-struckmeier A, Mohr H. A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. J Immunol Methods, 1989, 119: 45–51. CrossRef
- Kawai K, Sasaki T, Saijou K,et al. Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay. Cancer Immunol Immunother, 1992, 35: 225–229. CrossRef
- Guo YJ, Che XY, Shen F,et al. Effective tumor vaccines generated byin vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nature, 1997, 3: 451–455. CrossRef
- Seo N, Tokura Y, Furukawa F,et al. Down-regulation of tumoricidal NK and NK T cell activities by MHC K b molecules expressed on Th2-type T and αβ T cells coinfiltrating in early B16 melanoma lesions. J Immunol, 1998, 161: 4138–4145.
- Falo LD Jr, Kovacsovics-Bankowski M, Thompson K,et al. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nature Med, 1995, 1: 649–653. CrossRef
- Harding CV, Song R. Phagocytic processing of exogenous particulate antigen by macrophages for presentation by clas MHC I molecules. J Immunol, 1994, 153: 4925–4933.
- Kovacsovics-Bankowski M, Clark K, Benacerraf B,et al. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci, 1993, 90: 4942–4946. CrossRef
- Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen MHC class I presentation pathway. J Immunol, 1996, 156: 3721–3726.
- Nair S, Zhou F, Reddy R,et al. Soluble protein delivered to dendritic cells via PH-sensitive liposomes induce primary cytotoxic T lymphocytes responsesin vitro. J Exp Med, 1992, 175: 609–612. CrossRef
- De Bruijn M, Jackson MR, Peterson PA. Phagocyte-induced antigen-specific activation of unprimed CD8+ T cellsin vitro. Eur J Immunol, 1995, 25: 1274–1285. CrossRef
- De Bruijn M, Peterson PA, Jackson MR. Induction of heat-stable antigen expression by phagocytosis is involved inin vitro activation of unprimed CTL by macrophages. J Immunol, 1996, 156: 2686–2692.
- Fernandez NC, Lozier A, Flament C,et al. Dendriitic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responsesin vivo. Nature Med, 1999, 5: 405–411. CrossRef
- Yan Y, Steinherz P, Klingemann HG,et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res, 1998, 4: 2859–2868.
- Fixed-tumor vaccine: A practical formulation with cytokine-microspheres for protective and therapeutic antitumor immunity
The Chinese-German Journal of Clinical Oncology
Volume 2, Issue 4 , pp 196-202
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- cancer vaccine
- cytotoxic T lymphocyte
- Author Affiliations
- 1. Department of Hepatobiliary Surgery, First Affiliated Hospital of Sun Yat-Sen University of Medical Science, 510080, Guangzhou, China
- 2. Riken Cell Bank, Riken (The Institute of Physical and Chemical Research), 3-1-1 Koyadai, 305-0074, Tsukuba Science City, Ibaraki, Japan
- 3. Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, 720 Rutland Avenue, 21205, Baltimore, MD